Follow-on roundup

At least six companies priced follow-ons, raising more than $600 million total.

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Tuesday through the sale of 4.4 million shares at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Goldman Sachs and

Read the full 479 word article

User Sign In